PharVision Advisers’s Norfolk Southern NSC Stock Holding History

PharVision Advisers’s Portfolio NSC Stock Details NSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,197	Closed	-$284K	–	376
2025 Q1	$284K	Buy	+1,197	New	+$292K	0.39%	102

Other funds holding NSC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

PharVision Advisers's NSC Position: Q2 2025 in Review

PharVision Advisers sold out of Norfolk Southern (NSC) in Q2 2025, closing a stake of 1,197 shares — an estimated $284K sold.

PharVision Advisers first reported a position in NSC in Q1 2025 and held it in 1 quarter. The position peaked at $284K in Q1 2025. 1,691 funds tracked by Wall St. Rank hold NSC as of Q2 2025.

PharVision Advisers reported no remaining Norfolk Southern position as of Q2 2025 after selling out during the quarter.
PharVision Advisers sold 1,197 Norfolk Southern shares in Q2 2025, an estimated $284K.
PharVision Advisers first reported a position in Norfolk Southern in Q1 2025 and held it in 1 quarter.
PharVision Advisers's Norfolk Southern position peaked at $284K in Q1 2025.
1,691 funds tracked by Wall St. Rank held Norfolk Southern as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.